Cipher Pharmaceuticals Valuation
Is CPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CPH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CPH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CPH?
Key metric: As CPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CPH's PE Ratio? | |
|---|---|
| PE Ratio | 17x |
| Earnings | US$15.86m |
| Market Cap | US$268.14m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.3x |
| Enterprise Value/EBITDA | 23.7x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does CPH's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.5x | ||
RX BioSyent | 18.3x | n/a | CA$126.5m |
GRIN Grown Rogue International | 40x | n/a | CA$213.4m |
HASH Simply Solventless Concentrates | 63x | n/a | CA$51.3m |
MDP Medexus Pharmaceuticals | 16.5x | 49.9% | CA$52.0m |
CPH Cipher Pharmaceuticals | 17x | 12.7% | CA$374.9m |
Price-To-Earnings vs Peers: CPH is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (34.5x).
Price to Earnings Ratio vs Industry
How does CPH's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
| 17 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 17 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CPH is good value based on its Price-To-Earnings Ratio (17x) compared to the North American Pharmaceuticals industry average (18.5x).
Price to Earnings Ratio vs Fair Ratio
What is CPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17x |
| Fair PE Ratio | 20.3x |
Price-To-Earnings vs Fair Ratio: CPH is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (20.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CA$14.72 | CA$16.70 +13.5% | 10.1% | CA$18.60 | CA$14.50 | n/a | 3 |
| Nov ’25 | CA$15.24 | CA$16.83 +10.5% | 10.9% | CA$19.00 | CA$14.50 | n/a | 3 |
| Oct ’25 | CA$14.69 | CA$16.17 +10.1% | 7.3% | CA$17.00 | CA$14.50 | n/a | 3 |
| Sep ’25 | CA$18.99 | CA$15.83 -16.6% | 6.5% | CA$17.00 | CA$14.50 | n/a | 3 |
| Aug ’25 | CA$12.34 | CA$13.67 +10.8% | 22.8% | CA$17.00 | CA$9.50 | n/a | 3 |
| Jul ’25 | CA$8.20 | CA$10.67 +30.1% | 8.0% | CA$11.50 | CA$9.50 | n/a | 3 |
| Jun ’25 | CA$8.76 | CA$10.67 +21.8% | 8.0% | CA$11.50 | CA$9.50 | n/a | 3 |
| May ’25 | CA$8.58 | CA$7.62 -11.2% | 19.9% | CA$9.25 | CA$5.60 | n/a | 3 |
| Apr ’25 | CA$8.11 | CA$7.62 -6.1% | 19.9% | CA$9.25 | CA$5.60 | n/a | 3 |
| Mar ’25 | CA$7.22 | CA$6.62 -8.4% | 15.3% | CA$8.00 | CA$5.60 | n/a | 3 |
| Feb ’25 | CA$5.90 | CA$5.53 -6.2% | 11.1% | CA$6.25 | CA$4.75 | n/a | 3 |
| Jan ’25 | CA$5.54 | CA$5.45 -1.6% | 9.6% | CA$6.00 | CA$4.75 | n/a | 3 |
| Dec ’24 | CA$6.33 | CA$5.45 -13.9% | 9.6% | CA$6.00 | CA$4.75 | n/a | 3 |
| Nov ’24 | CA$4.39 | CA$4.33 -1.3% | 7.2% | CA$4.75 | CA$4.00 | CA$15.24 | 3 |
| Oct ’24 | CA$4.25 | CA$4.33 +2.0% | 7.2% | CA$4.75 | CA$4.00 | CA$14.69 | 3 |
| Sep ’24 | CA$3.97 | CA$4.33 +9.2% | 7.2% | CA$4.75 | CA$4.00 | CA$18.99 | 3 |
| Aug ’24 | CA$3.66 | CA$4.33 +18.4% | 7.2% | CA$4.75 | CA$4.00 | CA$12.34 | 3 |
| Jul ’24 | CA$3.57 | CA$4.33 +21.4% | 7.2% | CA$4.75 | CA$4.00 | CA$8.20 | 3 |
| Jun ’24 | CA$3.91 | CA$4.33 +10.8% | 7.2% | CA$4.75 | CA$4.00 | CA$8.76 | 3 |
| May ’24 | CA$3.43 | CA$4.13 +20.3% | 3.0% | CA$4.25 | CA$4.00 | CA$8.58 | 2 |
| Apr ’24 | CA$3.30 | CA$4.13 +25.0% | 3.0% | CA$4.25 | CA$4.00 | CA$8.11 | 2 |
| Mar ’24 | CA$3.78 | CA$4.13 +9.1% | 3.0% | CA$4.25 | CA$4.00 | CA$7.22 | 2 |
| Feb ’24 | CA$3.42 | CA$4.13 +20.8% | 3.0% | CA$4.25 | CA$4.00 | CA$5.90 | 2 |
| Jan ’24 | CA$3.84 | CA$4.13 +7.4% | 3.0% | CA$4.25 | CA$4.00 | CA$5.54 | 2 |
| Dec ’23 | CA$3.47 | CA$4.13 +18.9% | 3.0% | CA$4.25 | CA$4.00 | CA$6.33 | 2 |
| Nov ’23 | CA$3.23 | CA$3.30 +2.2% | 6.1% | CA$3.50 | CA$3.10 | CA$4.39 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fennec Pharmaceuticals
US$117.3m
Operates as a biopharmaceutical company in the United States.
FRX
US$6.50
7D
7.6%
1Y
-44.2%
Medexus Pharmaceuticals
CA$52.0m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.15
7D
5.4%
1Y
40.5%
Verano Holdings
CA$850.9m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.32
7D
-12.8%
1Y
-60.6%